Takeda Pharmaceutical (TKPHF) Cash from Investing Activities (2018 - 2026)

Takeda Pharmaceutical's Cash from Investing Activities history runs 9 years deep, the most recent figure standing at -$369.9 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 186.78% year-over-year to -$369.9 million; the TTM figure through Mar 2026 stood at -$2.4 billion (down 0.83% YoY), while the FY2026 annual figure was -$2.5 billion, down 1.77% from the prior year.
• Cash from Investing Activities was -$369.9 million for Q1 2026 at Takeda Pharmaceutical, up from -$1.5 billion in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of -$129.0 million in Q1 2025 to a low of -$3.3 billion in Q1 2023.
• Historically, Cash from Investing Activities has averaged -$759.0 million across 5 years, with a median of -$419.5 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities tumbled 1402.64% in 2023, then soared 87.48% in 2024.
• A 5-year view of Cash from Investing Activities shows it stood at -$330.5 million in 2022, then sank by 54.08% to -$509.2 million in 2023, then tumbled by 49.27% to -$760.1 million in 2024, then sank by 96.45% to -$1.5 billion in 2025, then jumped by 75.22% to -$369.9 million in 2026.
• The last three Cash from Investing Activities figures came in at -$369.9 million (Q1 2026), -$1.5 billion (Q4 2025), and -$326.7 million (Q3 2025), per Business Quant data.